• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性血栓栓塞性肺动脉高压的遗传性和获得性血栓形成危险因素。

Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension.

作者信息

Wong Chieh L, Szydlo Richard, Gibbs Simon, Laffan Mike

机构信息

Haematology Department, Hammersmith Hospital, Imperial College Academic Health Science Centre, London, UK.

出版信息

Blood Coagul Fibrinolysis. 2010 Apr;21(3):201-6. doi: 10.1097/MBC.0b013e328331e664.

DOI:10.1097/MBC.0b013e328331e664
PMID:20182352
Abstract

The role of thrombosis and hereditary thrombotic risk factors in the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) and non-CTEPH is not clear. We retrospectively analyzed the frequency of hereditary and acquired thrombotic risk factors in 245 patients with pulmonary hypertension, of whom 45 had CTEPH and 200 had non-CTEPH. Nine of 31 (29%) white patients with CTEPH versus 10 of 129 (7.8%) patients with non-CTEPH were heterozygous for factor V Leiden (FVL; P = 0.001). Contrary to other studies, antiphospholipid antibodies (APA) were not increased. Elevated factor VIII (FVIII) and von Willebrand factor (VWF; >1.5 U/ml) were common in CTEPH and non-CTEPH, although significantly higher (P = 0.01 for FVIII and 0.009 for VWF) in CTEPH versus non-CTEPH. There was no correlation between FVIII-VWF and fibrinogen levels in the CTEPH group (P = 0.84 for FVIII and 0.49 for VWF) but a strong correlation between FVIII-VWF and fibrinogen in the non-CTEPH (P < 0.0001). There was no association between FVIII-VWF and WHO functional status in the CTEPH group although there was a strong correlation (P < 0.001) between the two parameters in the non-CTEPH group. For equivalent WHO functional class, FVIII levels were significantly higher (P = 0.007) in the CTEPH group. We have found no association between FVIII-VWF levels and oxygen saturation in both groups of patients. The results indicate different pathophysiologies for CTEPH and non-CTEPH. The elevation of FVIII and increased incidence of FVL gene polymorphisms in the CTEPH group support a primary role of thrombosis in aetiology.

摘要

血栓形成及遗传性血栓形成危险因素在慢性血栓栓塞性肺动脉高压(CTEPH)和非CTEPH发病机制中的作用尚不清楚。我们回顾性分析了245例肺动脉高压患者中遗传性和获得性血栓形成危险因素的发生频率,其中45例患有CTEPH,200例患有非CTEPH。31例白人CTEPH患者中有9例(29%)与129例非CTEPH患者中有10例(7.8%)为因子V莱顿(FVL)杂合子(P = 0.001)。与其他研究相反,抗磷脂抗体(APA)并未增加。CTEPH和非CTEPH患者中因子VIII(FVIII)和血管性血友病因子(VWF;>1.5 U/ml)升高较为常见,尽管CTEPH患者中的水平显著高于非CTEPH患者(FVIII为P = 0.01,VWF为P = 0.009)。CTEPH组中FVIII-VWF与纤维蛋白原水平之间无相关性(FVIII为P = 0.84,VWF为P = 0.49),但非CTEPH组中FVIII-VWF与纤维蛋白原之间存在强相关性(P < 0.0001)。CTEPH组中FVIII-VWF与世界卫生组织(WHO)功能状态之间无关联,而非CTEPH组中这两个参数之间存在强相关性(P < 0.001)。对于同等的WHO功能分级,CTEPH组中的FVIII水平显著更高(P = 0.007)。我们发现两组患者的FVIII-VWF水平与血氧饱和度之间均无关联。结果表明CTEPH和非CTEPH具有不同的病理生理学机制。CTEPH组中FVIII升高及FVL基因多态性发生率增加支持血栓形成在病因学中的主要作用。

相似文献

1
Hereditary and acquired thrombotic risk factors for chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压的遗传性和获得性血栓形成危险因素。
Blood Coagul Fibrinolysis. 2010 Apr;21(3):201-6. doi: 10.1097/MBC.0b013e328331e664.
2
Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.凝血因子VIII/血管性血友病因子复合物对凝血因子V莱顿突变杂合子携带者活化蛋白C抵抗表型及静脉血栓栓塞风险的影响。
Blood Coagul Fibrinolysis. 1999 Oct;10(7):409-16.
3
von Willebrand factor and factor VIII: C in acute cerebrovascular disease. Relationship to stroke subtype and mortality.急性脑血管疾病中的血管性血友病因子和凝血因子 VIII:C。与卒中亚型及死亡率的关系。
Thromb Haemost. 1997 Jun;77(6):1104-8.
4
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension.慢性血栓栓塞性肺动脉高压中凝血因子VIII升高的高患病率。
Thromb Haemost. 2003 Sep;90(3):372-6. doi: 10.1160/TH03-02-0067.
5
Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.血友病 A 携带者和对照女性血浆因子 VIII 水平的决定因素。
Haemophilia. 2010 Jan;16(1):111-7. doi: 10.1111/j.1365-2516.2009.02108.x. Epub 2009 Sep 16.
6
Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis.对用于诊断血管性血友病的实验室参数重新评估ABO血型、性别和年龄:对诊断的潜在影响与血栓形成风险的潜在关联。
Am J Clin Pathol. 2005 Dec;124(6):910-7.
7
Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism.遗传性出血性毛细血管扩张症(HHT)中因子VIII升高:与静脉血栓栓塞的关联
Thromb Haemost. 2007 Nov;98(5):1031-9.
8
Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals.血栓形成患者和对照个体中ABO及分泌型基因型与血浆VIII因子和血管性血友病因子水平的关系。
Br J Haematol. 2005 Jan;128(1):100-7. doi: 10.1111/j.1365-2141.2004.05249.x.
9
[Risk factors in chronic thromboembolic pulmonary hypertension].[慢性血栓栓塞性肺动脉高压的危险因素]
Arch Bronconeumol. 2009 Jun;45 Suppl 6:11-4. doi: 10.1016/S0300-2896(09)73497-0.
10
Thrombosis risk in systemic lupus erythematosus: the role of thrombophilic risk factors.系统性红斑狼疮的血栓形成风险:血栓形成倾向危险因素的作用。
Scand J Rheumatol. 2007 May-Jun;36(3):198-205. doi: 10.1080/03009740601089283.

引用本文的文献

1
Chronic Thromboembolic Pulmonary Hypertension in Latvia: Epidemiological Insights and Diagnostic Challenges From 2024.拉脱维亚的慢性血栓栓塞性肺动脉高压:2024年的流行病学见解与诊断挑战
Pulm Circ. 2025 Sep 3;15(3):e70159. doi: 10.1002/pul2.70159. eCollection 2025 Jul.
2
Association of Fibrinogen Aα Thr312Ala (rs6050) Polymorphism with Venous Thrombosis and Chronic Thromboembolic Pulmonary Hypertension: A Meta-Analysis.纤维蛋白原Aα Thr312Ala(rs6050)多态性与静脉血栓形成及慢性血栓栓塞性肺动脉高压的关联:一项荟萃分析
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251314476. doi: 10.1177/10760296251314476.
3
Molecular Pathophysiology of Chronic Thromboembolic Pulmonary Hypertension: A Clinical Update from a Basic Research Perspective.
慢性血栓栓塞性肺动脉高压的分子病理生理学:基于基础研究视角的临床进展
Adv Respir Med. 2024 Nov 27;92(6):485-503. doi: 10.3390/arm92060044.
4
From Pulmonary Embolism to Chronic Thromboembolic Pulmonary Hypertension: A Pathophysiological Approach.从肺栓塞到慢性血栓栓塞性肺动脉高压:一种病理生理学方法。
Rev Cardiovasc Med. 2024 Nov 18;25(11):402. doi: 10.31083/j.rcm2511402. eCollection 2024 Nov.
5
Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review.遗传性出血性毛细血管扩张症中的肺动脉高压:一项临床综述。
Pulm Circ. 2023 Oct 19;13(4):e12301. doi: 10.1002/pul2.12301. eCollection 2023 Oct.
6
Prevalence, Genetic Background, and Clinical Phenotype of Congenital Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension.慢性血栓栓塞性肺动脉高压中先天性血栓形成倾向的患病率、遗传背景及临床表型
JACC Asia. 2022 May 17;2(3):247-255. doi: 10.1016/j.jacasi.2022.02.010. eCollection 2022 Jun.
7
Chronic Thromboembolic Pulmonary Hypertension.慢性血栓栓塞性肺动脉高压
Lung. 2022 Jun;200(3):283-299. doi: 10.1007/s00408-022-00539-w. Epub 2022 May 29.
8
Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension.鉴定慢性血栓栓塞性肺动脉高压患者中的新型变异。
J Am Heart Assoc. 2020 Nov 3;9(21):e015902. doi: 10.1161/JAHA.120.015902. Epub 2020 Oct 24.
9
Evaluation of the Incidence of Chronic Thromboembolic Pulmonary Hypertension 1 Year After First Episode of Acute Pulmonary Embolism: A Cohort Study.急性肺栓塞首次发作后 1 年慢性血栓栓塞性肺动脉高压发生率的评估:一项队列研究。
Lung. 2020 Feb;198(1):59-64. doi: 10.1007/s00408-019-00315-3. Epub 2020 Jan 2.
10
Research progress on the pathogenesis of CTEPH.CTEPH 的发病机制研究进展。
Heart Fail Rev. 2019 Nov;24(6):1031-1040. doi: 10.1007/s10741-019-09802-4.